PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21465480-8 2012 Decreased GTP-induced vimentin Ser56 phosphorylation and secretion resulted from inhibition of Cdk5 activity by roscovitine or olomoucine or by depletion of Cdk5 by siRNA, suggesting that GTP-induced Cdk5-mediated vimentin Ser56 phosphorylation may be related to GTP-induced Cdk5-mediated secretion by neutrophils. olomoucine 127-137 cyclin dependent kinase 5 Homo sapiens 95-99 31983427-4 2020 Using patch-clamp electrophysiology, we show that Cdk5 inhibition by Olomoucine significantly increases current density through CaV1.3 (L-type) channels heterologously expressed in HEK293 cells. olomoucine 69-79 cyclin dependent kinase 5 Homo sapiens 50-54 15033170-6 2004 Administration of Cdk5 inhibitors, roscovitine and olomoucine, into the crushed nerves resulted in decreases in Cdk5 kinase activity in nerves and retardation of nerve fiber regrowth. olomoucine 51-61 cyclin dependent kinase 5 Homo sapiens 18-22 18948252-2 2008 In turn, activated CDK5 phosphorylates the Rho family GTP-binding protein TC10alpha on threonine 197 that is sensitive to the CDK5 inhibitor olomoucine and blocked by small interfering RNA-mediated knockdown of CDK5. olomoucine 141-151 cyclin dependent kinase 5 Homo sapiens 19-23 18948252-2 2008 In turn, activated CDK5 phosphorylates the Rho family GTP-binding protein TC10alpha on threonine 197 that is sensitive to the CDK5 inhibitor olomoucine and blocked by small interfering RNA-mediated knockdown of CDK5. olomoucine 141-151 cyclin dependent kinase 5 Homo sapiens 126-130 18948252-2 2008 In turn, activated CDK5 phosphorylates the Rho family GTP-binding protein TC10alpha on threonine 197 that is sensitive to the CDK5 inhibitor olomoucine and blocked by small interfering RNA-mediated knockdown of CDK5. olomoucine 141-151 cyclin dependent kinase 5 Homo sapiens 126-130 16815303-3 2006 Intraventricular injections of olomoucine and U-0126 (CDK5 and MAP kinase inhibitors, respectively) inhibited hyperphosphorylation. olomoucine 31-41 cyclin dependent kinase 5 Homo sapiens 54-58 15033170-6 2004 Administration of Cdk5 inhibitors, roscovitine and olomoucine, into the crushed nerves resulted in decreases in Cdk5 kinase activity in nerves and retardation of nerve fiber regrowth. olomoucine 51-61 cyclin dependent kinase 5 Homo sapiens 112-116 10770290-7 2000 We show here that up-regulation of Cdk5 does not occur in granulocytic differentiation, whereas inhibition of Cdk5 activity by olomoucine, or its expression by a plasmid construct expressing antisense Cdk5, switches the 1,25D3-induced monocytic phenotype (a combination of positive nonspecific esterase reaction, expression of the CD14 marker, and morphology) to general myeloid phenotype (positive nitro-blue tetrazolium reaction, CD11b marker and morphology). olomoucine 127-137 cyclin dependent kinase 5 Homo sapiens 110-114 11743029-3 2001 Moreover, antisense oligonucleotide suppression of Cdk5 or p35 in young cultured neurons, as well as inhibition of Cdk5 activity with olomoucine, blocks the formation of membrane vesicles from the Golgi apparatus. olomoucine 134-144 cyclin dependent kinase 5 Homo sapiens 115-119 10770290-7 2000 We show here that up-regulation of Cdk5 does not occur in granulocytic differentiation, whereas inhibition of Cdk5 activity by olomoucine, or its expression by a plasmid construct expressing antisense Cdk5, switches the 1,25D3-induced monocytic phenotype (a combination of positive nonspecific esterase reaction, expression of the CD14 marker, and morphology) to general myeloid phenotype (positive nitro-blue tetrazolium reaction, CD11b marker and morphology). olomoucine 127-137 cyclin dependent kinase 5 Homo sapiens 110-114 9933594-8 1999 Inhibition of Cdk5 with olomoucine decreased evoked norepinephrine secretion from chromaffin cells, an effect not observed with the inactive analogue iso-olomoucine. olomoucine 24-34 cyclin dependent kinase 5 Homo sapiens 14-18